Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187856 | 0.83 | STAT3 (0.47) | ELANE | |
| SCHEMBL187599 | 0.78 | MAPT (0.51) | MAPTELANEKDM4EALDH1A1HTT | |
| SCHEMBL12309491 | 0.77 | MAPT (0.52) | MAPTELANEKDM4EALDH1A1HTT | |
| SCHEMBL12670684 | 0.77 | KDM4E (0.58) | MAPTELANEKDM4E | |
| SCHEMBL187541 | 0.75 | KDM4E (0.56) | MAPTELANEKDM4EALDH1A1POLB | |
| SCHEMBL12309527 | 0.74 | MAPT (0.47) | MAPT | |
| SCHEMBL187838 | 0.74 | MAPT (0.51) | MAPTELANEKDM4EALDH1A1POLB | |
| SCHEMBL12670692 | 0.73 | ELANE (0.54) | MAPTELANEKDM4EPOLB | |
| SCHEMBL2800784 | 0.71 | TSHR (0.54) | ELANEKDM4EALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL120324 | 0.70 | TSHR (0.67) | MAPTKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993616-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8829040-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20130252955-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-09-26 | — | — | US | disclosed |
| EP-2133332-B1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL (JP) | 2013-09-18 | — | — | EP | disclosed |
| EP-2402314-B1 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-8466152-B2 | (aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2013-06-18 | — | — | US | disclosed |
| EP-2402314-A1 | (Aza)indole derivative and use thereof for medical purposes | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-8003647-B2 | (Aza)indole derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2133332-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056521-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | MAPT 4787/4885ELANE 943/4885KDM4E 399/4885 |
| US-20140179932-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | MAPT 4787/4885ELANE 943/4885KDM4E 399/4885 |
| US-20130252955-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | MAPT 4787/4885ELANE 943/4885KDM4E 399/4885 |
| US-20110230454-A1 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, DAO, TDO2 | MAPT 4787/4885ELANE 943/4885KDM4E 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.